Third Rock Ventures launches Goldfinch Bio with $55M Series A
December 16, 2016
Biotechnology | Cambridge, MA | Series A
Third Rock Ventures has announced the launch of Goldfinch Bio, a company focused on discovering and developing precision therapies for patients with kidney disease. Along with investing in the newly formed company, a handful of the firm’s management will serve as interim executives: Phil Reilly will be interim Chief Medical Officer, Neil Exter will be COO and Abbie Celniker will lead as interim CEO.